ERBB2 and non-small cell lung carcinoma: Of the nine assessable patients with NSCLC harboring HER-2 mutations, two patients achieved a PR (ORR of 22%), four patients exhibited SD (DCR of 67%), and most side effects were grade 1–2 (Table 5)125.